Comparative evaluation of the immune responses and protection engendered by LC16m8 and dryvax smallpox vaccines in a mouse model

Clinical and Vaccine Immunology

Volumn 16, Issue 9, 2009, Pages 1261-1271

  Meseda, Clement A ^a   Mayer, Anne E ^a   Kumar, Arunima ^a   Garcia, Alonzo D ^a   Campbell, Joseph ^a   Listrani, Paul ^a   Manischewitz, Jody ^a   King, Lisa R ^a   Golding, Hana ^a   Merchlinsky, Michael ^a   Weir, Jerry P ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; LC 16M8; SMALLPOX VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; GENE MUTATION; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IN VITRO STUDY; INOCULATION; JAPAN; KIDNEY CELL; LETHAL DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SMALLPOX; VACCINATION; VACCINIA VIRUS; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; BODY WEIGHT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; SMALLPOX; SMALLPOX VACCINE; SURVIVAL ANALYSIS;

EID: 69749114351     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00040-09     Document Type: Article

References (41)

1. Aldaz-Carroll, L., J. C. Whitbeck, M. Ponce de Leon, H. Lou, L. Hirao, S. N. Isaacs, B. Moss, R. J. Eisenberg, and G. H. Cohen. 2005. Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J. Virol. 79:6260-6271. (Pubitemid 40617230)
2. Barefoot, B., N. J. Thornburg, D. H. Barouch, J.-S. Yu, C. Sample, R. E. Johnston, H. X. Liao, T. B. Kepler, B. F. Haynes, and E. Ramsburg. 2008. Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. Vaccine 26:6108-6118.
3. Bell, E., M. Shamim, J. C. Whitbeck, G. Sfyroera, J. D. Lambris, and S. N. Isaacs. 2004. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 325:425-431. (Pubitemid 38902805)
4. Breman, J. G., R. Kalisa, M. V. Steniowski, E. Zanotto, A. I. Gromyko, and I. Arita. 1980. Human monkeypox, 1970-79. Bull. W. H. O. 58:165-182.
5. Centers for Disease Control and Prevention. 2003. Multistate outbreak of monkeypox - Illinois, Indiana, and Wisconsin. MMWR Morb. Mortal. Wkly. Rep. 52:537-540.
6. Drexler, I., C. Staib, W. Kastenmuller, S. Stevanovic, B. Schmidt, F. A. Lemonnier, H. G. Rammensee, D. H. Busch, H. Bernhard, V. Erfle, and G. Sutter. 2003. Identification of vaccinia virus epitope-specific HLA-A*0201- restricted T cells and comparative analysis of smallpox vaccines. Proc. Natl. Acad. Sci. USA 100:217-222.
7. Empig, C., J. R. Kenner, M. Perret-Gentil, B. E. Youree, E. Bell, A. Chen, M. Gurwith, K. Higgins, M. Lock, A. D. Rice, J. Schriewer, F. Sinangil, E. White, R. M. Buller, T. S. Dermody, S. N. Isaacs, and R. W. Moyer. 2006. Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. Vaccine 24:3686-3694.
8. Fogg, C., S. Lustig, J. C. Whitbeck, R. J. Eisenberg, G. H. Cohen, and B. Moss. 2004. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J. Virol. 78:10230-10237. (Pubitemid 39258347)
9. Galmiche, M. C., J. Goenaga, R. Wittek, and L. Rindisbacher. 1999. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 254:71-80. (Pubitemid 29391715)
10. Garcia, A. D., C. A. Meseda, A. E. Mayer, A. Kumar, M. Merchlinsky, and J. P. Weir. 2007. Characterization and use of mammalian-expressed vaccinia virus extracellular membrane proteins for quantification of the humoral immune response to smallpox vaccines. Clin. Vaccine Immunol. 14:1032-1044.
11. Golovkin, M., S. Spitsin, V. Andrianov, Y. Smirnov, Y. Xiao, N. Pogrebnyak, K. Markley, R. Brodzik, Y. Gleba, S. N. Isaacs, and H. Koprowski. 2007. Smallpox subunit vaccine produced in planta confers protection in mice. Proc. Natl. Acad. Sci. USA 104:6864-6869.
12. Greenberg, R. N., J. S. Kennedy, D. J. Clanton, E. A. Plummer, L. Hague, J. Cruz, F. A. Ennis, W. C. Blackwelder, and R. J. Hopkins. 2005. Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calflymph derived vaccine: a blind, single-centre, randomised controlled trial. Lancet 365:398-409.
13. Hashizume, S., H. Yoshizawa, M. Morita, and K. Suzuki. 1985. Properties of attenuated mutant of vaccinia virus LC16m8, derived from Lister strain, p. 87-99. In G. V. Quinnan, Jr. (ed.), Vaccinia viruses as vectors for vaccine antigens. Elsevier Science Publishing Co., Inc., San Diego, CA.
14. Heraud, J. M., Y. Edghill-Smith, V. Ayala, I. Kalisz, J. Parrino, V. S. Kalyanaraman, J. Manischewitz, L. R. King, A. Hryniewicz, C. J. Trindade, M. Hassett, W. P. Tsai, D. Venzon, A. Nalca, M. Vaccari, P. Silvera, M. Bray, B. S. Graham, H. Golding, J. W. Hooper, and G. Franchini. 2006. Subunit recombinant vaccine protects against monkeypox. J. Immunol. 177:2552-2564. (Pubitemid 44201014)
15. Hooper, J. W., D. M. Custer, C. S. Schmaljohn, and A. L. Schmaljohn. 2000. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 266:329-339.
16. Hooper, J. W., E. Thompson, C. Wilhelmsen, M. Zimmerman, M. A. Ichou, S. E. Steffen, C. S. Schmaljohn, A. L. Schmaljohn, and P. B. Jahrling. 2004. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 78:4433-4443.
17. Jezek, Z., S. S. Marennikova, M. Mutumbo, J. H. Nakano, K. M. Paluku, and M. Szczeniowski. 1986. Human monkeypox: a study of 2,510 contacts of 214 patients. J. Infect. Dis. 154:551-555.
18. Jones-Trower, A., A. Garcia, C. A. Meseda, Y. He, C. Weiss, A. Kumar, J. P. Weir, and M. Merchlinsky. 2005. Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin. Virology 343:128-140. (Pubitemid 41572239)
19. Karupiah, G., V. Panchanathan, I. Sakala, and G. Chaudhri. 2007. Genetic resistance to smallpox; lessons from mouse. Novartis Found. Symp. 281:129-140.
20. Kenner, J., F. Cameron, C. Empig, D. V. Jobes, and M. Gurwith. 2006. LC16m8: an attenuated smallpox vaccine. Vaccine 24:7009-7022.
21. Kidokoro, M., M. Tashiro, and H. Shida. 2005. Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc. Natl. Acad. Sci. USA 102:4152-4157.
22. Law, M., and G. L. Smith. 2001. Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology 280:132-142. (Pubitemid 34158059)
23. Lawrence, S. J., K. R. Lottenbach, F. K. Newman, R. M. Buller, C. J. Bellone, J. J. Chen, G. H. Cohen, R. J. Eisenberg, R. B. Belshe, S. L. Stanley, Jr., and S. E. Frey. 2007. Antibody responses to vaccinia membrane proteins after smallpox vaccination. J. Infect. Dis. 196:220-229.
24. Manischewitz, J., L. R. King, N. A. Bleckwenn, J. Shiloach, R. Taffs, M. Merchlinsky, N. Eller, M. G. Mikolajczyk, D. J. Clanton, T. Monath, R. A. Weltzin, D. E. Scott, and H. Golding. 2003. Development of a novel vaccinia-neutralization assay based on reporter-gene expression. J. Infect. Dis. 188: 440-448.
25. Mayr, A., H. Stickl, H. K. Muller, K. Danner, and H. Singer. 1978. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zentralbl. Bakteriol. B 167:375-390. (In German.)
26. Meseda, C. A., K. L. Elkins, M. J. Merchlinsky, and J. P. Weir. 2002. Prime-boost immunization with DNA and modified vaccinia virus Ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone. J. Infect. Dis. 186:1065-1073.
27. Meseda, C. A., A. D. Garcia, A. Kumar, A. E. Mayer, J. Manischewitz, L. R. King, H. Golding, M. Merchlinsky, and J. P. Weir. 2005. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 339:164-175.
28. Morikawa, S., T. Sakiyama, H. Hasegawa, M. Saijo, A. Maeda, I. Kurane, G. Maeno, J. Kimura, C. Hirama, T. Yoshida, Y. Asahi-Ozaki, T. Sata, T. Kurata, and A. Kojima. 2005. An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection. J. Virol. 79:11873-11891. (Pubitemid 41279305)
29. Pulford, D. J., A. Gates, S. H. Bridge, J. H. Robinson, and D. Ulaeto. 2004. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge. Vaccine 22:3358-3366.
30. Putz, M. M., C. M. Midgley, M. Law, and G. L. Smith. 2006. Quantification of antibody responses against multiple antigens of the two infectious forms of vaccinia virus provides a benchmark for smallpox vaccination. Nat. Med. 12:1310-1315.
31. Reed, K. D., J. W. Melski, M. B. Graham, R. L. Regnery, M. J. Sotir, M. V. Wegner, J. J. Kazmierczak, E. J. Stratman, Y. Li, J. A. Fairley, G. R. Swain, V. A. Olson, E. K. Sargent, S. C. Kehl, M. A. Frace, R. Kline, S. L. Foldy, J. P. Davis, and I. K. Damon. 2004. The detection of monkeypox in humans in the Western Hemisphere. N. Engl. J. Med. 350:342-350.
32. Saijo, M., Y. Ami, Y. Suzaki, N. Nagata, N. Iwata, H. Hasegawa, M. Ogata, S. Fukushi, T. Mizutani, T. Sata, T. Kurata, I. Kurane, and S. Morikawa. 2006. LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox. J. Virol. 80:5179-5188. (Pubitemid 43752763)
33. Smerdou, C., and P. Liljestrom. 1999. Non-viral amplification systems for gene transfer: vectors based on alphaviruses. Curr. Opin. Mol. Ther. 1:244-251.
34. Smerdou, C., and P. Liljestrom. 1999. Two-helper RNA system for production of recombinant Semliki forest virus particles. J. Virol. 73:1092-1098. (Pubitemid 29036760)
35. Smith, G. L., and A. Vanderplasschen. 1998. Extracellular enveloped vaccinia virus. Entry, egress, and evasion. Adv. Exp. Med. Biol. 440:395-414.
36. Smith, G. L., A. Vanderplasschen, and M. Law. 2002. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 83:2915-2931.
37. Sugimoto, M., and K. Yamanouchi. 1994. Characteristics of an attenuated vaccinia virus strain, LC16m0, and its recombinant virus vaccines. Vaccine 12:675-681. (Pubitemid 24182365)
38. Takahashi-Nishimaki, F., S. Funahashi, K. Miki, S. Hashizume, and M. Sugimoto. 1991. Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins. Virology 181:158-164.
39. Tang, J., M. Murtadha, M. Schnell, L. C. Eisenlohr, J. Hooper, and P. Flomenberg. 2006. Human T-cell responses to vaccinia virus envelope proteins. J. Virol. 80:10010-10020. (Pubitemid 44522595)
40. Tscharke, D. C., G. Karupiah, J. Zhou, T. Palmore, K. R. Irvine, S. M. Haeryfar, S. Williams, J. Sidney, A. Sette, J. R. Bennink, and J. W. Yewdell. 2005. Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J. Exp. Med. 201:95-104.
41. Viner, K. M., and S. N. Isaacs. 2005. Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccinees. Microbes Infect. 7:579-583.